

# Diabetes and its related conditions

Early detection and monitoring is crucial for better patient outcomes

## Diabetes is usually accompanied by other conditions

Cardiovascular diseases account for

**33% to 50%** of all diabetes-related deaths.<sup>1</sup>

**Up to 80%**

of type 2 diabetes patients are also affected by nonalcoholic fatty liver disease (NAFLD).<sup>2</sup>

**Around 17%**

of live births are affected by hyperglycemia in pregnancy.<sup>3</sup>

**7-11%** of people with diabetes are affected by diabetic foot and lower limb complications.<sup>1</sup>

**80%** of all end-stage kidney disease is caused by diabetes, hypertension, or a combination of both.<sup>1</sup>

**45%** of people with diabetes are undiagnosed,<sup>3</sup> or diabetes recognized only when life-threatening complications develop.



**Testing is critical to provide timely care.**

## Hemoglobin A1c is an important indicator of long-term glycemic control

Monitoring long-term glucose helps minimize the complications caused by chronically elevated glucose levels. For every **1%** reduction in results of HbA1c blood tests, there is a:<sup>4</sup>

**40%** reduction in the risk of developing eye, kidney, and nerve disease

**14%** reduction in the risk of heart attack

## Test with confidence to manage related conditions



### Cardiac tests

Expanding menu of tests, including high-sensitivity troponin I, to help manage patients throughout the continuum of cardiovascular disease




### Liver fibrosis test

The Enhanced Liver Fibrosis (ELF™) Test is the first blood test granted De Novo marketing authorization by the FDA and is recommended by an extensive list of international physician associations for NAFLD or nonalcoholic steatohepatitis (NASH) management




### Kidney tests

Comprehensive testing for kidney disease management, from in-office urine tests to accurate estimation of residual renal function in dialysis patients



### Atellica® CH Enzymatic HbA1c test

- High precision and accuracy with the enzymatic methodology
- Cost-effective, easy to implement, and less prone to testing interferences
- High-throughput, integrated solution to meet your HbA1c testing demands
- Confidence in results with IFCC-standardized and NGSP-certified assay



## The right tests to provide the right care at the right time

1. <https://idf.org/aboutdiabetes/complications.html>

2. Younossi ZM, et al. Hepatology. 2016;64:73-84

3. IDF diabetes atlas 2021. 10th edition. Available from: [www.diabetesatlas.org](http://www.diabetesatlas.org).

4. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853. IBID.

Product availability is subject to local regulatory requirements, and therefore availability may vary by country.

Published by Siemens Healthcare Diagnostics Inc. - Order No. 30-22-DX-1754-76 - 10-2022  
© Siemens Healthcare Diagnostics Inc., 2022